Active, not recruitingPhase 3NCT06131554
A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
Studying Meningococcal meningitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CanSino Biologics Inc.
- Principal Investigator
- Isti Suharjanti, DrHusada Utama Hospital
- Intervention
- batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)(biological)
- Enrollment
- 1480 target
- Eligibility
- 18-55 years · All sexes
- Timeline
- 2024 – 2025
Study locations (1)
- Husada Utama Hospital, Surabaya, Indonesia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06131554 on ClinicalTrials.govOther trials for Meningococcal meningitis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06995430A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)GlaxoSmithKline
- RECRUITINGPHASE4NCT06832514Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender PersonsUniversity Ghent
- ACTIVE NOT RECRUITINGPHASE3NCT06700148A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year OldsCanSino Biologics Inc.
- ACTIVE NOT RECRUITINGPHASE3NCT06226714A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year OldsCanSino Biologics Inc.
- RECRUITINGNCT04664569National Bacterial Meningitis StudyAssociation Clinique Thérapeutique Infantile du val de Marne